Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer
Non-Small Cell Lung Carcinoma
Explore 1,128 assets in Non-Small Cell Lung Carcinoma →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Pfizer
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00907504CT.gov Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT00673049CT.gov Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer | — | Terminated | — | — | — |
NCT00596830CT.gov Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | — | Terminated | — | — | — |
NCT00603538CT.gov Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer | — | Completed | — | — | — |
NCT00560573CT.gov Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00147537CT.gov Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer (this asset) | Pfizer | P3 | CCC · 50 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Neoplasm | — | P2 | CCC · 51 |
| Prostate Neoplasm | — | P2 | CCC · 50 |
| Squamous Cell Carcinoma | — | P3 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G2, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Cp-751,871 Clone 2.13.2 Heavy Chain) Disulphide With Human Monoclonal Cp-751,871 Clone 2.13.2 Light Chain, Dimer in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g2-anti-human-insulin-like-growth-factor-i-receptor-human-monoclonal-cp-751871-clone-2132-heavy-chain-disulphide-with-human-monoclonal-cp-751871-clone-2132-light-chain-dimer-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →